Evidence map›Paper›PMID 28031369›Full record

ArticleJournal of virology2017

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Usha K Nivarthi, Nurgun Kose, Gopal Sapparapu, Douglas Widman, Emily Gallichotte, Jennifer M Pfaff, Benjamin J Doranz, Daniela Weiskopf, Alessandro Sette, Anna P Durbin and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 51 citations in OpenAlex.

  1. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Trial
  2. Trial
  3. CD4Vaccines · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Usha K NivarthiDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Nurgun KoseThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gopal SapparapuThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Douglas WidmanDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Emily GallichotteDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Jennifer M PfaffIntegral Molecular Inc., Philadelphia, Pennsylvania, USA.
Benjamin J DoranzIntegral Molecular Inc., Philadelphia, Pennsylvania, USA.
Daniela WeiskopfLa Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Alessandro SetteLa Jolla Institute for Allergy and Immunology, La Jolla, California, USA.
Anna P DurbinJohns Hopkins Bloomberg School of Public Health, Department of International Health, Baltimore, Maryland, USA.
Steve S WhiteheadLaboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, Maryland, USA.
Ralph BaricDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
James E CroweThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA james.crowe@vanderbilt.edu aravinda_desilva@med.unc.edu.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA james.crowe@vanderbilt.edu aravinda_desilva@med.unc.edu.
University of North Carolina at Chapel Hill · USVanderbilt University Medical Center · USIntegral Molecular (United States) · USLa Jolla Institute for Immunology · USJohns Hopkins University · USNational Institute of Allergy and Infectious Diseases · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)ZIAAI000987 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$37.9M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2015 to 2026
$34.1M
Translational CoreU19AI109761 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARIC, RALPH S · 2014 to 2018
$32.6M
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACYR01AI125198 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2016 to 2020
$5.7M
Molecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3M
NIAID NIH HHS P01 AI106695NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI107731NIAID NIH HHS R01 AI125198NIAID NIH HHS U19 AI109761
6 · The paper itself

Abstract

The four dengue virus (DENV) serotypes are mosquito-borne flaviviruses responsible for dengue fever and dengue hemorrhagic fever. People exposed to DENV develop antibodies (Abs) that strongly neutralize the serotype responsible for infection. Historically, infection with DENV serotype 4 (DENV4) has been less common and less studied than infections with the other three serotypes. However, DENV4 has been responsible for recent large and sustained epidemics in Asia and Latin America. The neutralizing antibody responses and the epitopes targeted against DENV4 have not been characterized in human infection. In this study, we mapped and characterized epitopes on DENV4 recognized by neutralizing antibodies in people previously exposed to DENV4 infections or to a live attenuated DENV4 vaccine. To study the fine specificity of DENV4 neutralizing human antibodies, B cells from two people exposed to DENV4 were immortalized and screened to identify DENV-specific clones. Two human monoclonal antibodies (MAbs) that neutralized DENV4 were isolated, and their epitopes were finely mapped using recombinant viruses and alanine scan mutation array techniques. Both antibodies bound to quaternary structure epitopes near the hinge region between envelope protein domain I (EDI) and EDII. In parallel, to characterize the serum neutralizing antibody responses, convalescence-phase serum samples from people previously exposed to primary DENV4 natural infections or a monovalent DENV4 vaccine were analyzed. Natural infection and vaccination also induced serum-neutralizing antibodies that targeted similar epitope domains at the EDI/II hinge region. These studies defined a target of neutralizing antigenic site on DENV4 targeted by human antibodies following natural infection or vaccination.

Indexed as

Adaptive ImmunityAedesAnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCell LineDengueDengue VirusEpitope MappingHumansImmunologic MemoryProtein BindingProtein DomainsVaccinationVaccines, AttenuatedAntibodies, NeutralizingAntibodies, ViralVaccines, AttenuatedViral Vaccinesantibody responsesDengue virus serotype 4epitopehumaninfectionmemory B cellsneutralizationvaccination

Identifiers

PMID28031369
PMCPMC5309932
OpenAlexW2565673565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.